Copenhagen, Denmark — December 2025 — Norlase, a global leader in next-generation ophthalmic laser technology, today announced key milestones that have made 2025 the most consequential year in the company’s history. After a year of extraordinary growth, multiple international product approvals, a groundbreaking product launch, prestigious industry recognition, and new strategic funding from the European Investment Bank (EIB), Norlase enters 2026 with exceptional commercial momentum and a strengthened global market position.
Breakthrough Innovation & Commercial Success
LYNX Launch in the United States and Europe (January 27, 2025)
Norlase launched LYNX, the world’s first Pattern Laser Indirect Ophthalmoscope (LIO), simultaneously in the United States and Europe, establishing a completely new category in retinal laser care. Console-free and battery-powered, LYNX brings pattern scanning laser delivery into an ultra-portable headset. Early adopters of LYNX report simplified workflows, enhanced clinical mobility, and more than 50% reduction in treatment time – dramatically expanding access to advanced retinal treatments across two of the largest ophthalmology markets in the world.
LYNX saw rapid global adoption, including by several of the world’s leading ophthalmic hospitals, and exceeded a global install of 100 units within its first year on the market. To learn more about the experience of two early adopters of LYNX, Beth Richter MD and Sid Schechet MD, check out their article in Ophthalmology Management.
PRISM Award Recognition (January 29, 2025)
Just 48 hours after launch, LYNX received the 2025 PRISM Award for Photonics Innovation, one of the industry’s most influential accolades – affirming both the technological breakthrough and the commercial potential of this first-of-its-kind platform.
Strategic Funding to Accelerate Global Expansion
European Investment Bank Funding Secured (February 27, 2025)
Norlase secured a €20 million investment facility from the European Investment Bank (EIB), enabling accelerated scaling of commercial operations, expansion of global manufacturing capacity, and fast-tracking of next-generation technology for eye-care. EIB is the leading provider of venture debt in Europe, helping the highest-potential growth companies on the continent scale. The financing represents a strong institutional endorsement of Norlase’s vision, technology platform, and long-term growth trajectory.
Global Regulatory Momentum and Major Market Access Milestones
Saudi Arabia Approval for LYNX (March 23, 2025)
The Saudi Food and Drug Authority granted approval for LYNX, positioning Norlase for rapid expansion in one of the Middle East’s most advanced ophthalmology markets. Norlase will support commercialization in the region in partnership with Saudi Services & Healthcare Co. Ltd.
LEAF Launch in China (Summer 2025)
Norlase achieved a major commercial milestone with the launch of LEAF in China. Together with one of the strongest distribution partners in China, Clinico, the launch brings ultra-portable green laser technology to a high-growth market with rising demand for mobility, efficiency, and simplified laser workflows.
LYNX Approval in Mexico (September 23, 2025)
COFEPRIS granted national approval for LYNX, strengthening Norlase’s commercial footprint across Latin America. Norlase will collaborate with Technomix to support distribution and market expansion throughout Mexico.
Approvals in India for LION, LEAF & ECHO (November 21, 2025)
India’s regulatory authorities granted approval for three major Norlase systems—LION, LEAF, and ECHO—simultaneously, unlocking one of the world’s largest ophthalmology markets and solidifying Norlase’s long-term commitment to expanding access in high-volume care environments. Norlase will work with its partner BioMedix Optotechnik & Devices Pvt Ltd to bring these technologies across India.
Global Brand Visibility & Product Pipeline Expansion
ESCRS Copenhagen: Distributor & Physician Headquarters Visits (September 2025)
As ESCRS returned to Copenhagen, Norlase hosted international distributors and key opinion leaders at its headquarters for technology demonstrations, strategy sessions, and early visibility into the company’s next-generation roadmap. These engagements strengthened commercial alignment and reinforced Norlase’s leadership in innovation.
ESCRS Copenhagen: Limited Launch of PMLT (September 2025)
During the congress, the company revealed the PMLT (Pattern MicroSecond Laser Trabeculoplasty) option for its ECHO pattern laser, to deliver a non-destructive treatment for patients with glaucoma. This extends Norlase’s pattern-based technology into the growing field of selective and sub-threshold laser therapy – marking a critical step in expanding the company’s addressable market beyond retina.
Positioned for Continued Growth in 2026
“Norlase’s achievements in 2025 reflect both the strength of our technology platform and the discipline of our global expansion strategy,” said Oliver Hvidt, CEO of Norlase. “A more than 40 percent increase in our global install base shows how quickly the market is shifting toward our technology. With LYNX now expanding across multiple major regions, new regulatory approvals accelerating adoption of LEAF, LION, and ECHO, and EIB funding enabling scale-up across Europe and Asia Pacific, Norlase enters 2026 with unmatched momentum. We remain committed to delivering innovations that simplify workflows, increase access, and improve outcomes for millions of patients worldwide.”
With a deepening commercial footprint, robust regulatory pipeline, and expanding technology platform, Norlase is well positioned to continue delivering long-term value to customers, partners, and investors.
About Norlase
Norlase is a Denmark-headquartered medical-device company developing next-generation ophthalmic laser solutions for retinal and glaucoma care. Leveraging proprietary MEMS miniaturization and direct-diode technology, Norlase designs ultra-compact, integrated, and workflow-simplifying laser systems used by ophthalmologists worldwide. The company’s portfolio includes LYNX, ECHO, LEAF, and LION, with additional innovations under development to advance eye-care globally.
DIDN’T FIND WHAT YOU’RE LOOKING FOR?
Let us know how we can help!
DIDN’T FIND WHAT YOU
WERE LOOKING FOR?
Let us know how we can help!
